VCIM
STLN

Velan Capital Investment Management’s Starling Oncology STLN Stock Holding History

Velan Capital Investment Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-548,841
Closed -$2.54M – 34
2022
Q3 		$2.54M Sell
548,841
-51,159
-9% -$301K 2.52% 11
2022
Q2 		$3.04M Hold
600,000
– – 3.08% 9
2022
Q1 		$4.28M Hold
600,000
– – 3.97% 10
2021
Q4 		$5.85M Buy
+600,000
New +$5.33M 4.54% 7

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Velan Capital Investment Management's STLN Position: Q4 2022 in Review

Velan Capital Investment Management sold out of Starling Oncology (STLN) in Q4 2022, closing a stake of 548,841 shares — an estimated $2.54M sold.

Velan Capital Investment Management first reported a position in STLN in Q4 2021 and held it in 4 quarters. The position peaked at $5.85M in Q4 2021. 41 funds tracked by Wall St. Rank hold STLN as of Q4 2022.

  • Velan Capital Investment Management reported no remaining Starling Oncology position as of Q4 2022 after selling out during the quarter.
  • Velan Capital Investment Management sold 548,841 Starling Oncology shares in Q4 2022, an estimated $2.54M.
  • Velan Capital Investment Management first reported a position in Starling Oncology in Q4 2021 and held it in 4 quarters.
  • Velan Capital Investment Management's Starling Oncology position peaked at $5.85M in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Starling Oncology as of Q4 2022.

Based on Velan Capital Investment Management's 13F filing for Q4 2022, filed 13 Feb 2023.